GENVEC files S-1 | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
GENVEC files S-1

An SI Board Since October 2000

Posts	SubjectMarks	Bans
30	9	0

Emcee: drshred	Type: Unmoderated

Introduction Compact

GenVec develops gene therapy products and has a lead to treat Heart Disease that is now in Ph II clinicals. The lead is a modified Human adenovirus non-RCA (that means it can't replicate) vector that carries an expression cassette for VEGF121, an angiogenic gene. The trade mark name is "BIOBYPASS".

GENVEC today has filed an S-1 with the SEC.
genvec.com

If the PhII clinicals come out good, this could be a BIG winner. Remember, that potentially therapeutic genes are available; it's the vehicle to deliver the genes to therapeutic locations that's the challenge.

If GenVec can demonstrate delivery and persistence of gene expression in this model, there will be many more theraputic applications to follow.

The Lead under writter is JP Morgan. -they don't have a habit of making bad bets... ever.

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
30	I just started another thread with an up-to-date original post and relevant info	caly	-	3/5/2010
29	I believe that the shares are still seriously under priced and that the increase	Gary Mohilner	-	12/1/2009
28	I just sold my shares at $1.07. While I like the company, the run to over a buc	Labrador	1	11/30/2009
27	No charge, but even if I'm wrong, I've never seen a stock with the poten	Gary Mohilner	-	11/29/2009
26	How much do you charge for your crystal ball?	DewDiligence_on_SI	-	11/29/2009
25	I cannot say precisely when, but I believe GNVC will break through it's 52 w	Gary Mohilner	-	11/29/2009
24	They need the partnership, as well as the manufacturing capability, before appro	Gary Mohilner	-	11/24/2009
23	GNVC should be able to strike a deal with Genentech/Roche or Amgen etc to manufa	ChinuSFO	-	11/20/2009
22	That's true and since I posted that the company has restated they don't	Gary Mohilner	-	10/16/2009
21	<i>>I don't know if anyone is still following this thread, but if s	DewDiligence_on_SI	-	10/14/2009
20	I don't know if anyone is still following this thread, but if so, people sho	Gary Mohilner	-	10/14/2009
19	I believe the beauty of TNFerade is its ability to work with nearly all other th	Gary Mohilner	-	7/27/2009
18	From Cancer Gene Therapy, a very positive review article on TNFerade that cover	pgo-neil	-	7/26/2009
17	The TNFerade KM curves are out: siliconinvestor.com	DewDiligence_on_SI	-	6/1/2009
16	GNVC will be presenting on Tuesday at the Bio Conference, is there anyone still	Gary Mohilner	-	2/8/2009
15	GNVC's Poster presentation at ASCO had some amazing data for victims of head	Gary Mohilner	-	5/31/2008
14	Rodman & Renshaw came out with an update on April 3, 2008. Here's their	Labrador	-	4/12/2008
13	Yes it is a good article. I followed McCamant's years ago when he was high	Gary Mohilner	-	4/7/2008
12	thestockadvisors.com Decent comments on Genvec within this article. I've	Labrador	-	4/6/2008
11	Is anyone here still interested in GNVC. I've just invested in the last few	Gary Mohilner	-	10/1/2007
10	GenVec Proprietary Adenovector and Gene Used to Restore Balance Function in Mice	LJM	-	2/6/2007
9	GenVec Announces First Patient Treated with TNFerade(TM) for Head and Neck Cance	LJM	-	1/26/2007
8	I was rather hoping this would come out before the contest ended. Lesson: if o	tuck	-	12/19/2006
7	GenVec Announces Efficacy Update in Phase II/III Clinical Trial of TNFerade(TM)	nigel bates	-	12/19/2006
6	>>Long-Term Results from TNFerade(TM) Pancreatic Cancer Study and Updated	tuck	-	5/24/2006

Go to reply# or date (mm/dd/yy):